Neurodegenerative Diseases
Ulysses Neuroscience provides a powerful translational platform for neurodegenerative disease research, integrating advanced biomarker technologies with human iPSC-derived neuronal models and preclinical sampling capabilities. Our Cherrywood laboratory houses all major biomarker platforms under one roof, enabling unmatched consistency and direct comparability between preclinical and clinical samples. From validated neurodegeneration panels to disease-relevant iPSC lines, we deliver the data precision and translational relevance required to advance disease-modifying therapeutics through development.
Explore Our Full Therapeutic Expertise
Beyond neuropsychiatric disorders, Ulysses Neuroscience delivers comprehensive preclinical and translational services across the spectrum of CNS conditions. Our integrated platform—combining behavioural pharmacology, advanced biomarker technologies, EEG, and human iPSC-derived models—enables seamless translation from bench to bedside across multiple therapeutic areas.
Neuropsychiatric
Diseases
- Depression & Treatment-Resistant Depression
- Anxiety Disorders
- Schizophrenia
Neurodegenerative Diseases
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Amyotrophic Lateral Sclerosis (ALS)
Neuromuscular
Diseases
- Charcot-Marie-Tooth Disease (CMT)
Neurodevelopmental Diseases
- CDKL5 Deficiency Disorder (CDD)
- Fragile X Syndrome (FXS)
- Epilepsy & Seizure Disorders
Psychedelics and
Neuroplastogens
- Classical psychedelics
- Next-generation non-hallucinogenic neuroplastogens.
